Stifel Nicolaus Keeps Their Buy Rating on HEALWELL AI (AIDX)
Stifel Nicolaus analyst Justin Keywood maintained a Buy rating on HEALWELL AI today and set a price target of C$3.10.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Keywood is an analyst with an average return of -3.8% and a 46.99% success rate. Keywood covers the Healthcare sector, focusing on stocks such as WELL Health Technologies Corp, kneat.com, and DRI Healthcare.
Currently, the analyst consensus on HEALWELL AI is a Strong Buy with an average price target of C$3.03.
Based on HEALWELL AI’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of C$30.35 million and a GAAP net loss of C$27.86 million. In comparison, last year the company earned a revenue of C$13.74 million and had a GAAP net loss of C$10.57 million
Read More on TSE:AIDX:
Disclaimer & DisclosureReport an Issue
- HEALWELL AI Expands DARWEN Platform’s Scientific Footprint With 47 Peer-Reviewed Studies
- HEALWELL AI Sets March Dates to Release 2025 Results and Brief Investors
- HEALWELL AI Wins Major U.S. HIE Deal as AI-Enabled Platform Gains Global Traction
- HEALWELL AI Steps Up Investor Outreach With March Conference Lineup
- HEALWELL AI: Scaling Government-Grade Healthcare AI With Recurring SaaS and Strategic Cross-Sell Synergies
